Program
datopotamab deruxtecan
Also written as “Dato-DXd”, “Datopotamab deruxtecan” and “Datopotamab Deruxtecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Triple Negative Breast Neoplasms · Endometrial Neoplasms · Urinary Bladder Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 2020 open or running | phase 3since Oct 4, 2021 | Oct 25, 2018 | Jan 11, 2027phase 3 · NCT06417814 |
| Daiichi Sankyo | 87 open or running | phase 3since Nov 19, 2020 | Jan 9, 2018 | Jan 1, 2028phase 1 · NCT03401385 |
Also a collaborator on its studies: Merck and parexel.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentAstraZeneca develops it with Daiichi Sankyo, worldwide except Japan, where Daiichi Sankyo keeps the rights.Announced Jul 27, 2020 · Source: Daiichi Sankyo and AstraZeneca (release), Jul 27, 2020
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Jan 9, 2018.
- Sep 22, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT05555732 · 1,233 enrolled · United States, Argentina, Australia and more
- Nov 4, 2022Phase 3 study in Breast NeoplasmsAstraZeneca · NCT05629585 · 1,174 enrolled · United States, Belgium, Brazil and more
- Dec 28, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05687266 · 1,350 enrolled · United States, Austria, Brazil and more
- Oct 12, 20232 phase 3 studies in Breast NeoplasmsAstraZeneca · NCT06112379, NCT06103864
- Apr 2, 20242 phase 3 studies in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06350097, NCT06357533
- May 13, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06417814 · 768 enrolled · United States, Australia, Belgium and more
- Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06564844 · 25 enrolled · United States, Brazil, Canada and more
- Jul 4, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT07098338 · 278 planned · United States, Australia, Canada and more
- Aug 12, 2025Phase 3 study in Urinary Bladder NeoplasmsDaiichi Sankyo · NCT07129993 · 630 planned · United States, Austria, China and more
- Sep 11, 2025Phase 3 study in Breast NeoplasmsAstraZeneca · NCT07205822 · 100 planned · United States, China, France and more
- Oct 28, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT07291037 · 400 planned · United States, Australia, Austria and more
- Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellAstraZeneca · NCT07720284 · 915 planned · United States, Australia, Brazil and more
- Oct 15, 2026Primary completion moved from 2026-09-30 to 2027-01-11Date moved laterphase 3 · +3 months · NCT06417814
- Oct 16, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT07890714 · 268 planned · Taiwan
Ahead
- Jan 11, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06417814
- Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT06103864
- Sep 1, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT05629585
- Oct 1, 2027Primary completion: phase 2 study in Endometrial NeoplasmsAstraZeneca · NCT05489211
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) ”NCIt, by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07890714Carcinoma, Non-Small-Cell Lung · Taiwan | 2 | Recruiting | Daiichi Sankyo | Sep 30, 2029 | 268 |
| NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more | 3 | Recruiting | AstraZeneca | Sep 11, 2030 | 915 |
| NCT07291037Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jan 29, 2029 | 400 |
| NCT07205822Breast Neoplasms · United States, China, France and more | 3 | Recruiting | AstraZeneca | Feb 2, 2028 | 100 |
| NCT07129993Urinary Bladder Neoplasms · United States, Austria, China and more | 3 | Recruiting | Daiichi Sankyo | Jun 1, 2029 | 630 |
| NCT07098338Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Recruiting | AstraZeneca | Apr 6, 2029 | 278 |
| NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more | 3 | Active, not recruiting | AstraZeneca | Jul 10, 2026 | 25 |
| NCT06417814Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jan 11, 2027 | 768 |
| NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Dec 28, 2029 | 675 |
| NCT06350097Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Recruiting | AstraZeneca | Mar 21, 2028 | 582 |
| NCT06103864Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Jul 28, 2027 | 625 |
| NCT06112379Breast Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Nov 20, 2028 | 1,902 |
| NCT05687266Carcinoma, Non-Small-Cell Lung · United States, Austria, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Nov 1, 2027 | 1,350 |
| NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Sep 1, 2027 | 1,174 |
| NCT05555732Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Daiichi Sankyo | May 11, 2029 | 1,233 |
| NCT05489211Endometrial Neoplasms · United States, Canada, China and more | 2 | Recruiting | AstraZeneca | Oct 1, 2027 | 454 |
| NCT05460273Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | AstraZeneca | Nov 7, 2023 | 119 |
| NCT05374512Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Aug 25, 2025 | 644 |
| NCT05215340Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Daiichi Sankyo | Mar 4, 2030 | 740 |
| NCT05104866Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jul 24, 2024 | 732 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | AstraZeneca | May 28, 2030 | 630 |
| NCT04656652Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Daiichi Sankyo | May 10, 2024 | 605 |
| NCT04612751Carcinoma, Non-Small-Cell Lung · United States, Belgium, Italy and more | 1 | Active, not recruiting | AstraZeneca | May 4, 2026 | 155 |
| NCT04526691Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more | 1 | Active, not recruiting | Daiichi Sankyo | Apr 14, 2024 | 145 |
| NCT04484142Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Completed | Daiichi Sankyo | Mar 10, 2023 | 137 |
| NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more | 2 | Active, not recruiting | AstraZeneca | May 6, 2025 | 247 |
| NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more | 2 | Active, not recruiting | AstraZeneca | Nov 29, 2024 | 243 |
| NCT03401385Triple Negative Breast Neoplasms · United States, Japan | 1 | Active, not recruiting | Daiichi Sankyo | Jan 1, 2028 | 890 |
How it is read
Names in the registry
- “Dato-DXd”, 12 entries
- “Datopotamab deruxtecan”, 5 entries
- “Datopotamab Deruxtecan”, 5 entries
- “Datopotamab deruxtecan (Dato-DXd)”, 2 entries
- “Datopotamab Deruxtecan (Dato-DXd)”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 17 studies
- Breast Neoplasms, 6 studies
- Triple Negative Breast Neoplasms, 2 studies
- Endometrial Neoplasms, 1 study
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.